Medigene Receives New US Patent for TCR-Modified T Cell Immunotherapy Medigene AG announced that the US Patent Office has issued patent No. 8,697,854 “High affinity T cell receptor and use thereof”, relating to T-cell receptors (TCRs) against the tumor associated antigen tyrosinase. [Medigene AG] Press Release Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing Avalanche Biotechnologies, Inc., a developer of gene therapies for serious eye diseases such as wet age-related macular degeneration, announced the successful completion of a $55 million Series B financing. [Avalanche Biotechnologies, Inc.] Press Release Orbsen Therapeutics in €6 Million Research Funding Success Orbsen Therapeutics is a spin-out from NUI Galway’s Regenerative Medicine Institute. MERLIN (MEsynchymal stem cells to Reduce Liver INflammation) will advance Orbsen’s proprietary cell therapy to a Phase IIa clinical trial in patients with inflammatory liver disease. [Orbsen Therapeutics] Press Release Athersys Announces Results from Phase II Study of MultiStem® Cell Therapy for Ulcerative Colitis Athersys, Inc. announced interim results from the Phase II clinical study of the administration of Athersys’ MultiStem® cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc. The cell therapy failed to show meaningful benefit, following a single administration, in patients suffering from chronic, moderate-to-severe UC who have failed other therapies. [Athersys, Inc.] Press Release FDA Approves Commencement of BrainStorm’s Phase II ALS Clinical Trial in U.S. BrainStorm Cell Therapeutics announced that the US Food and Drug Administration (FDA) has approved commencement of its Phase II clinical trial with NurOwnâ„¢ in patients with Amyotrophic Lateral Sclerosis (ALS). [BrainStorm Cell Therapeutics, Inc.] Press Release Bioheart Announces Clinical Study for Chronic Obstructive Pulmonary Disease Bioheart, Inc. announced that it will enroll patients in a new study for chronic obstructive pulmonary disease (COPD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCellâ„¢ in patients with COPD. [Bioheart, Inc.] Press Release Pluristem’s Manufacturing Facility Approved by European Auditors for Phase III Trials Pluristem Therapeutics Inc. announced that its new manufacturing facility has received the European Union’s Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell therapies manufactured at its facility in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III. [Pluristem Therapeutics Inc.] Press Release Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine’s 100 Most Influential People in the World Advanced Cell Technology, Inc. announced that the company’s Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world. [Advanced Cell Technology, Inc.] Press Release |